CninMed – China Innovative Drugs Update

Announced Date: 2025-10-21 (October 21, 2025) Asset Name: IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC)，IBI3001 (EGFR/B7H3 ADC) Licensor … [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on  Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)Read more

Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Pregene Biopharma (China) Licensee (Buyer):  KitePharma (Gliead) . … [China BD 2025] Pregene Biopharma and KitePharma (Gliead) enters a 1.64 Billion USD License on In vivo CAR-TRead more

Announced Date: 2025-10-17 (October 17, 2025) Licensor (Seller): Hansoh Pharma (China) Licensee (Buyer):  Roche . Asset … [China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110Read more

Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Nanjing Leads Biolabs (China) Licensee (Buyer):  Dianthus Therapeutics … [China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF/APRIL inhibitorRead more

Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): HaiHe Biopharma (China) Licensee (Buyer):  Taiho Pharmaceutical  (JP) … [China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3Kα Inhibitor Risovalisib (CYH33)Read more

Announced Date: 2025-10-08 (October 8, 2025) Asset Name: BTK inhibitor Orelabrutinib; Oral IL-17AA/AF inhibitor; Oral TYK2 … [China BD 2025] InnoCare Pharma and Zenas BioPharma enters 2 Billion USD License on Three Autoimmune Product CandidatesRead more

Asset Name: IBI324 (OLN324) Licensor (Seller): Innovent Biologics (China) Licensee (Buyer):  Ollin Biosciences (US) . Asset … [Unannounced Deal] Innovent and Ollin entered a License for VEGF/Ang2 Bispecific Antibody IBI324 (OLN324)Read more